Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: One step forward for overcoming anti-angiogenic drug resistance?
Angiogenesis is a pivotal process for growth, invasion and spread of the majority of solid tumors including melanoma. Anti-angiogenic agents have not been systematically tested in patients with advanced melanoma. Clinical efficacy of angiogenesis inhibitors targeting endothelial cells has not been a...
Gespeichert in:
| Veröffentlicht in: | Molecular oncology 2011-04, Vol.5 (2), p.137-149 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 149 |
|---|---|
| container_issue | 2 |
| container_start_page | 137 |
| container_title | Molecular oncology |
| container_volume | 5 |
| creator | Helfrich, Iris Schadendorf, Dirk |
| description | Angiogenesis is a pivotal process for growth, invasion and spread of the majority of solid tumors including melanoma. Anti-angiogenic agents have not been systematically tested in patients with advanced melanoma. Clinical efficacy of angiogenesis inhibitors targeting endothelial cells has not been as affirmative as initially hoped and improved clinical outcomes have been observed in combination with chemotherapy or additional drugs for many types of human cancer. However, angiogenesis is not only dependent on endothelial cell invasion and proliferation, it also requires pericyte coverage of vascular sprouts for stabilization and maturation of vascular walls. Recent data suggest that pericytes might be able to confer resistance to anti-vascular endothelial growth factor (VEGF) therapy. This review will focus on the significance of the vascular phenotype but also on the impact of pericyte-mediated vessel maturation for the susceptibility to anti-angiogenic therapy, including malignant melanoma, which we identified as crucial factor regarding therapeutic efficacy. |
| doi_str_mv | 10.1016/j.molonc.2011.01.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_24P</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5528279</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1574789111000196</els_id><sourcerecordid>864782141</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6447-3a99f327f510bbd6a62aed07c824cee6bb96faed52befc577d3e8073642af2a53</originalsourceid><addsrcrecordid>eNqNUk1v1DAQjRCIlsI_QMgSBy5ksZ3YTjhQQcWXtGgvcLYcZ5J65djBdrba_8KPxcuWUjigSmP5683TzJtXFE8JXhFM-KvtavLWO72imJAVzoGre8UpaURTYsrJ_Xxmoi5F05KT4lGMW4wZb3n7sDihpKqZYPS0-PHOet-jHcQIFk0qLUEl491LtFNRL1YFNF-C82k_A1Kuz2s0fgRnNJp9ApeMssi4nGrN6JRLaAKrnJ_Ua7RxgGKCGQ0-XKnQH3bkdxC0n4wbM1cy5S3CPiwjChBNTMppOH9cPBiUjfDkej8rvn14__XiU7nefPx88XZdal7XoqxU2w4VFQMjuOt6rjhV0GOhG1prAN51LR_yC6MdDJoJ0VfQYFHxmqqBKladFW-OvPPSTdDr3FVQVs7BTCrspVdG_v3jzKUc_U4yRhsq2kzw4pog-O8LxCQnEzXYLAT4JcqGt3kUWfw7IGvRUFKTjHz-D3Lrl-CyDpLStiW1YL_46iNKBx9jgOGmaoLlwSdyK48-kQefSJwDVznt2e2Ob5J-GyMDzo-AK2NhfydS-WWzpoc7yyzij6iQJ7czEGTUBvJYexNAJ9l78_8afwI6BukO</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2299147596</pqid></control><display><type>article</type><title>Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: One step forward for overcoming anti-angiogenic drug resistance?</title><source>Wiley Online Library (Open Access Collection)</source><creator>Helfrich, Iris ; Schadendorf, Dirk</creator><creatorcontrib>Helfrich, Iris ; Schadendorf, Dirk</creatorcontrib><description>Angiogenesis is a pivotal process for growth, invasion and spread of the majority of solid tumors including melanoma. Anti-angiogenic agents have not been systematically tested in patients with advanced melanoma. Clinical efficacy of angiogenesis inhibitors targeting endothelial cells has not been as affirmative as initially hoped and improved clinical outcomes have been observed in combination with chemotherapy or additional drugs for many types of human cancer. However, angiogenesis is not only dependent on endothelial cell invasion and proliferation, it also requires pericyte coverage of vascular sprouts for stabilization and maturation of vascular walls. Recent data suggest that pericytes might be able to confer resistance to anti-vascular endothelial growth factor (VEGF) therapy. This review will focus on the significance of the vascular phenotype but also on the impact of pericyte-mediated vessel maturation for the susceptibility to anti-angiogenic therapy, including malignant melanoma, which we identified as crucial factor regarding therapeutic efficacy.</description><identifier>ISSN: 1574-7891</identifier><identifier>EISSN: 1878-0261</identifier><identifier>DOI: 10.1016/j.molonc.2011.01.003</identifier><identifier>PMID: 21345752</identifier><language>eng</language><publisher>United States: Elsevier B.V</publisher><subject>Angiogenesis ; Angiogenesis inhibitors ; Angiogenesis Inhibitors - pharmacology ; Angiogenesis Inhibitors - therapeutic use ; Animals ; anti-Angiogenic therapy ; Blood Vessels - drug effects ; Blood Vessels - pathology ; Cell growth ; Chemotherapy ; Clinical trials ; Drug resistance ; Drug Resistance, Neoplasm ; Endothelial cells ; Genotype & phenotype ; Humans ; Hypoxia ; Kinases ; Maturation ; Medical prognosis ; Medical research ; Melanoma ; Melanoma - blood supply ; Melanoma - drug therapy ; Melanoma - pathology ; Metabolism ; Metastasis ; Neovascularization, Pathologic - drug therapy ; Neovascularization, Pathologic - pathology ; Nitric oxide ; Pericytes ; Pericytes - drug effects ; Pericytes - pathology ; Phenotypes ; Review ; Reviews ; Skin cancer ; Smooth muscle ; Solid tumors ; Tumors ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factors - antagonists & inhibitors ; Vessel maturation</subject><ispartof>Molecular oncology, 2011-04, Vol.5 (2), p.137-149</ispartof><rights>2011 Federation of European Biochemical Societies</rights><rights>Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.</rights><rights>2011. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6447-3a99f327f510bbd6a62aed07c824cee6bb96faed52befc577d3e8073642af2a53</citedby><cites>FETCH-LOGICAL-c6447-3a99f327f510bbd6a62aed07c824cee6bb96faed52befc577d3e8073642af2a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528279/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.molonc.2011.01.003$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1417,3550,11562,27924,27925,45574,45575,45995,46052,46476,53791,53793</link.rule.ids><linktorsrc>$$Uhttps://onlinelibrary.wiley.com/doi/abs/10.1016%2Fj.molonc.2011.01.003$$EView_record_in_Wiley-Blackwell$$FView_record_in_$$GWiley-Blackwell</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21345752$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Helfrich, Iris</creatorcontrib><creatorcontrib>Schadendorf, Dirk</creatorcontrib><title>Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: One step forward for overcoming anti-angiogenic drug resistance?</title><title>Molecular oncology</title><addtitle>Mol Oncol</addtitle><description>Angiogenesis is a pivotal process for growth, invasion and spread of the majority of solid tumors including melanoma. Anti-angiogenic agents have not been systematically tested in patients with advanced melanoma. Clinical efficacy of angiogenesis inhibitors targeting endothelial cells has not been as affirmative as initially hoped and improved clinical outcomes have been observed in combination with chemotherapy or additional drugs for many types of human cancer. However, angiogenesis is not only dependent on endothelial cell invasion and proliferation, it also requires pericyte coverage of vascular sprouts for stabilization and maturation of vascular walls. Recent data suggest that pericytes might be able to confer resistance to anti-vascular endothelial growth factor (VEGF) therapy. This review will focus on the significance of the vascular phenotype but also on the impact of pericyte-mediated vessel maturation for the susceptibility to anti-angiogenic therapy, including malignant melanoma, which we identified as crucial factor regarding therapeutic efficacy.</description><subject>Angiogenesis</subject><subject>Angiogenesis inhibitors</subject><subject>Angiogenesis Inhibitors - pharmacology</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Animals</subject><subject>anti-Angiogenic therapy</subject><subject>Blood Vessels - drug effects</subject><subject>Blood Vessels - pathology</subject><subject>Cell growth</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm</subject><subject>Endothelial cells</subject><subject>Genotype & phenotype</subject><subject>Humans</subject><subject>Hypoxia</subject><subject>Kinases</subject><subject>Maturation</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Melanoma</subject><subject>Melanoma - blood supply</subject><subject>Melanoma - drug therapy</subject><subject>Melanoma - pathology</subject><subject>Metabolism</subject><subject>Metastasis</subject><subject>Neovascularization, Pathologic - drug therapy</subject><subject>Neovascularization, Pathologic - pathology</subject><subject>Nitric oxide</subject><subject>Pericytes</subject><subject>Pericytes - drug effects</subject><subject>Pericytes - pathology</subject><subject>Phenotypes</subject><subject>Review</subject><subject>Reviews</subject><subject>Skin cancer</subject><subject>Smooth muscle</subject><subject>Solid tumors</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factors - antagonists & inhibitors</subject><subject>Vessel maturation</subject><issn>1574-7891</issn><issn>1878-0261</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNUk1v1DAQjRCIlsI_QMgSBy5ksZ3YTjhQQcWXtGgvcLYcZ5J65djBdrba_8KPxcuWUjigSmP5683TzJtXFE8JXhFM-KvtavLWO72imJAVzoGre8UpaURTYsrJ_Xxmoi5F05KT4lGMW4wZb3n7sDihpKqZYPS0-PHOet-jHcQIFk0qLUEl491LtFNRL1YFNF-C82k_A1Kuz2s0fgRnNJp9ApeMssi4nGrN6JRLaAKrnJ_Ua7RxgGKCGQ0-XKnQH3bkdxC0n4wbM1cy5S3CPiwjChBNTMppOH9cPBiUjfDkej8rvn14__XiU7nefPx88XZdal7XoqxU2w4VFQMjuOt6rjhV0GOhG1prAN51LR_yC6MdDJoJ0VfQYFHxmqqBKladFW-OvPPSTdDr3FVQVs7BTCrspVdG_v3jzKUc_U4yRhsq2kzw4pog-O8LxCQnEzXYLAT4JcqGt3kUWfw7IGvRUFKTjHz-D3Lrl-CyDpLStiW1YL_46iNKBx9jgOGmaoLlwSdyK48-kQefSJwDVznt2e2Ob5J-GyMDzo-AK2NhfydS-WWzpoc7yyzij6iQJ7czEGTUBvJYexNAJ9l78_8afwI6BukO</recordid><startdate>201104</startdate><enddate>201104</enddate><creator>Helfrich, Iris</creator><creator>Schadendorf, Dirk</creator><general>Elsevier B.V</general><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope></search><sort><creationdate>201104</creationdate><title>Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: One step forward for overcoming anti-angiogenic drug resistance?</title><author>Helfrich, Iris ; Schadendorf, Dirk</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6447-3a99f327f510bbd6a62aed07c824cee6bb96faed52befc577d3e8073642af2a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Angiogenesis</topic><topic>Angiogenesis inhibitors</topic><topic>Angiogenesis Inhibitors - pharmacology</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Animals</topic><topic>anti-Angiogenic therapy</topic><topic>Blood Vessels - drug effects</topic><topic>Blood Vessels - pathology</topic><topic>Cell growth</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm</topic><topic>Endothelial cells</topic><topic>Genotype & phenotype</topic><topic>Humans</topic><topic>Hypoxia</topic><topic>Kinases</topic><topic>Maturation</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Melanoma</topic><topic>Melanoma - blood supply</topic><topic>Melanoma - drug therapy</topic><topic>Melanoma - pathology</topic><topic>Metabolism</topic><topic>Metastasis</topic><topic>Neovascularization, Pathologic - drug therapy</topic><topic>Neovascularization, Pathologic - pathology</topic><topic>Nitric oxide</topic><topic>Pericytes</topic><topic>Pericytes - drug effects</topic><topic>Pericytes - pathology</topic><topic>Phenotypes</topic><topic>Review</topic><topic>Reviews</topic><topic>Skin cancer</topic><topic>Smooth muscle</topic><topic>Solid tumors</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factors - antagonists & inhibitors</topic><topic>Vessel maturation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Helfrich, Iris</creatorcontrib><creatorcontrib>Schadendorf, Dirk</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Helfrich, Iris</au><au>Schadendorf, Dirk</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: One step forward for overcoming anti-angiogenic drug resistance?</atitle><jtitle>Molecular oncology</jtitle><addtitle>Mol Oncol</addtitle><date>2011-04</date><risdate>2011</risdate><volume>5</volume><issue>2</issue><spage>137</spage><epage>149</epage><pages>137-149</pages><issn>1574-7891</issn><eissn>1878-0261</eissn><abstract>Angiogenesis is a pivotal process for growth, invasion and spread of the majority of solid tumors including melanoma. Anti-angiogenic agents have not been systematically tested in patients with advanced melanoma. Clinical efficacy of angiogenesis inhibitors targeting endothelial cells has not been as affirmative as initially hoped and improved clinical outcomes have been observed in combination with chemotherapy or additional drugs for many types of human cancer. However, angiogenesis is not only dependent on endothelial cell invasion and proliferation, it also requires pericyte coverage of vascular sprouts for stabilization and maturation of vascular walls. Recent data suggest that pericytes might be able to confer resistance to anti-vascular endothelial growth factor (VEGF) therapy. This review will focus on the significance of the vascular phenotype but also on the impact of pericyte-mediated vessel maturation for the susceptibility to anti-angiogenic therapy, including malignant melanoma, which we identified as crucial factor regarding therapeutic efficacy.</abstract><cop>United States</cop><pub>Elsevier B.V</pub><pmid>21345752</pmid><doi>10.1016/j.molonc.2011.01.003</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1574-7891 |
| ispartof | Molecular oncology, 2011-04, Vol.5 (2), p.137-149 |
| issn | 1574-7891 1878-0261 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5528279 |
| source | Wiley Online Library (Open Access Collection) |
| subjects | Angiogenesis Angiogenesis inhibitors Angiogenesis Inhibitors - pharmacology Angiogenesis Inhibitors - therapeutic use Animals anti-Angiogenic therapy Blood Vessels - drug effects Blood Vessels - pathology Cell growth Chemotherapy Clinical trials Drug resistance Drug Resistance, Neoplasm Endothelial cells Genotype & phenotype Humans Hypoxia Kinases Maturation Medical prognosis Medical research Melanoma Melanoma - blood supply Melanoma - drug therapy Melanoma - pathology Metabolism Metastasis Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - pathology Nitric oxide Pericytes Pericytes - drug effects Pericytes - pathology Phenotypes Review Reviews Skin cancer Smooth muscle Solid tumors Tumors Vascular endothelial growth factor Vascular Endothelial Growth Factors - antagonists & inhibitors Vessel maturation |
| title | Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: One step forward for overcoming anti-angiogenic drug resistance? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T18%3A04%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_24P&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Blood%20vessel%20maturation,%20vascular%20phenotype%20and%20angiogenic%20potential%20in%20malignant%20melanoma:%20One%20step%20forward%20for%20overcoming%20anti-angiogenic%20drug%20resistance?&rft.jtitle=Molecular%20oncology&rft.au=Helfrich,%20Iris&rft.date=2011-04&rft.volume=5&rft.issue=2&rft.spage=137&rft.epage=149&rft.pages=137-149&rft.issn=1574-7891&rft.eissn=1878-0261&rft_id=info:doi/10.1016/j.molonc.2011.01.003&rft_dat=%3Cproquest_24P%3E864782141%3C/proquest_24P%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2299147596&rft_id=info:pmid/21345752&rft_els_id=S1574789111000196&rfr_iscdi=true |